OBI Pharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, OBI Pharma sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
OBI Pharma: 7 sponsored US clinical trials, 1 recruiting.
OBI Pharma sponsors 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumor, with 2 trials.
Upper-quartile sponsor footprint
OBI Pharma sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
NCT07124117
A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
NCT06480240
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
NCT03562637
Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors
NCT04084366
A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
NCT03592264
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
NCT03573544
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
NCT01516307
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the OBI Pharma pipeline
1 recruiting of 7 indexed (14% open); 1 completed (14%).
Phase mix: 1 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Advanced Solid Tumor (2 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
OBI Pharma: open-pipeline peers nationwide
Peers matched on 7 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
OBI Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
Related
What to do with this OBI Pharma page
7 registered trials is a research-attention snapshot, not an endorsement of OBI Pharma or any single study.
- 1 of OBI Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Solid Tumor is the condition OBI Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumor trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
OBI Pharma pipeline card: 7 registered trials from official public datasets.Report a data error.